Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment
Trial Parameters
Brief Summary
This protocol aims to evaluate how NMT affects pediatric nasal microbiome diversity following intranasal mupirocin treatment
Eligibility Criteria
Child: Inclusion criteria 1. Child has had a prior nasal surveillance culture grow S. aurues 2. Child is \<18 years of age 3. Child completed treatment with intranasal mupirocin for S. aureus nasal colonization as part of routine clinical care two or more days before the planned transplant 4. Child has anticipated hospital length of stay \>3 days after completing intranasal mupirocin treatment 5. Infant \>25 weeks gestation unless \>2 months chronological age Exclusion criteria 1. Child is a ward of the State 2. Child with a diagnosis of immunodeficiency or antenatal suspicion for immunodeficiency (e.g., sibling with known immunodeficiency, genetic syndrome with known associated immunodeficiency) 3. Child cannot have nasal swabs collected (due to anatomic or other clinical intervention, including nasal packing) Donor: Inclusion criteria 1. Donor is able to provide informed consent 2. Donor has a relationship with the child outside of the hospital setting (i.e., not an ICU caregiver) Ex